ORCHPHARMA Orchid Pharma Q1 FY27 results (Apr–Jun 2026) and concall
Orchid Pharma reported a strong start to FY27 with a 15% YoY revenue growth to INR304 crores and a significant EBITDA improvement to INR25 crores, driven by better gross margins. The company is progressing with its strategic projects, 7-ACA and Cefiderocol, targeting commissioning by December 2026. While pricing pressure persists in non-regulated markets, management anticipates improved demand from regulated products in the coming quarters and is focused on cost discipline and product mix improvement.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 15.6%, net profit up 156.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 223 | 217 | 237 | 263 | 194 −13% | 207 −5% | 368 +55% | 304 +16% |
| EBITDA | 30 | 26 | 28 | -6 | -1 −105% | 2 −94% | 30 +8% | 14 +348% |
| Net profit | 27 | 21 | 22 | -6 | -6 −121% | -13 −161% | 26 +16% | 3 +157% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
